Durvalumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Durvalumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Durvalumab Today - Breaking & Trending Today

Durvalumab Confirmed Beneficial After NSCLC Chemoradiotherapy

This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.
....

United States , Shawm Durvalulmab , Us Flatiron Health , Eastern Cooperative Oncology Group , Image Credit , American Journal ,

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma. ....

Tyrosine Kinase Inhibitors , Unresectable Hepatocellular Carcinoma , Hepatocellular Carcinoma , Transarterial Chemoembolization , Launch Study , Emerald 1 Study ,

Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC

Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.

....

Charlson Comorbidity Index , Durvalumab Consolidation , Pacific Trial ,

Pneumonitis Risk in NSCLC Remains Uncertain, Obesity May Be Predictor

Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.
....

United States , Thoracic Disease , Computing Infrastructure ,

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization. ....

Riccardo Lencioni , Department Of Surgery , Critical Area Pathology , Druvalumab And Bevacizumab Plus Tace , Hepatocellular Carcinoma , Gastrointestinal Cancer , Gi Cancer , Asco Gi , Transarterial Chemoembolization , Phase 3 Emerald 1 Trial , 2024 Gastrointestinal Cancers Symposium , Università Di Pisa ,